ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

By Akshay Kedari  Date: 2020-04-14

ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

ThermoGenesis Holdings, Inc. has recently announced the acquisition of intellectual property by ImmuneCyte Life Sciences, its joint venture. The acquisition has been made by ThermoGenesis, a market leader and pioneer in the development & commercialization of automated cell processing technologies, to develop full human antibody therapeutics for COVID-19 disease.

The intellectual property that has been procured includes 4 monoclonal antibody drug candidates with high affinity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as tools for quantifying and screening efficacy of the neutralizing antibodies. These high-affinity antibodies have been obtained by screening the enriched libraries of B cell from people who have recovered from the COVID-19 disease recently. These technologies were developed by a team of researchers who work under East China Normal University, which is a prestigious university in China. The deal also includes an upfront cash payment for an undisclosed sum as well as low double-digit revenue sharing for the drug candidates.

The recent acquisition is another step towards the development of drug candidates or vaccine for emergency treatment of the patients infected by coronavirus. The convalescent plasma therapy has been applied for this treatment by giving current patients an infusion of plasma from individuals recovered from the disease. ThermoGenesis is developing this therapy by using its IgG/IgM Antibody Fast Detection Kit for SARS-CoV-2. Through the combination of this detection kit with the newly acquired technology by ImmuneCyte, the company will detect individuals who have acquired protective immunity against the coronavirus. Its proprietary cell processing platform will then allow the simultaneous isolation of immune cells and convalescent plasma for the effective development of potential anti-COVID-19 antibody.

The entrance of coronavirus into the cells can be blocked effectively by neutralizing antibodies, which are key effectors in the convalescent plasma, thus achieving anti-viral effects. The recent acquisition can lead to the further development of purified anti-COVID-19 monoclonal and polyclonal neutralizing antibodies as these can be more potent and safer with higher efficacy as compared to convalescent plasma.

Source credit:

https://thermogenesis.com/thermogenesis-announces-its-immunecyte-joint-venture-acquires-key-technologies-to-develop-fully-human-polyclonal-and-monoclonal-antibody-therapeutics-for-covid-19/

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Klevu launches Discovery Suite to boost online retail conversion rates

Klevu launches Discovery Suite to boost online retail conversion rates

By Akshay Kedari

Klevu Oy, a leading provider of AI-based search technologies for online retailers, has reportedly launched a comprehensive solution called Discovery Suite that can allow brands to capture shoppers’ intent in order to improve their conversion ra...

SK Group acquires 16.3% stake in VinCommerce for USD 410 million

SK Group acquires 16.3% stake in VinCommerce for USD 410 million

By Akshay Kedari

SK Group of South Korea has purchased 16.3% of Vincommerce, Vietnams leading retail business operator, for USD 410 million in a bid to broaden its presence in the Southeast Asian region’s customer retailer sector. Sources close to the matter s...

Snapchat exploring options to bypass Apple’s upcoming privacy policies

Snapchat exploring options to bypass Apple’s upcoming privacy policies

By Akshay Kedari

Reportedly, American camera and social media company Snap Inc. is exploring different methods to circumvent Apple’s upcoming privacy regulations which will prohibit apps from collecting iPhone user information. Apple’s highly controversi...

SK Innovation might pull its battery business from the United States

SK Innovation might pull its battery business from the United States

By Akshay Kedari

SK Innovation Co., a South Korea-based petrochemical, energy, and e-mobility battery manufacturer, has recently announced its plans of withdrawing its battery operations from America if U.S. President Joe Biden fails to overrule a trade panel decisio...

Jeep planning to establish EV charging networks near off-road routes

Jeep planning to establish EV charging networks near off-road routes

By Akshay Kedari

Jeep, the American multinational automobile manufacturer, is reportedly planning to develop EV charging networks near or at off-road routes across several locations in the U.S, in a bid to look beyond conventional roads and to offer consistent chargi...